Evidence-based use of colony-stimulating factors in elderly cancer patients (Q35599074)

9 August 2017

1 reference

title

Evidence-based use of colony-stimulating factors in elderly cancer patients (English)

1 reference

9 August 2017

Gary H Lyman

1 reference

9 August 2017

Nicole Kuderer

series ordinal

1 reference

9 August 2017

Olayemi Agboola

series ordinal

1 reference

9 August 2017

Lodovico Balducci

series ordinal

1 reference

9 August 2017

publication date

1 November 2003

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

487-499

1 reference

9 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Cancer Care in the Elderly: Cost and Quality-of-Life Considerations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Comorbidity and functional status are independent in older cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Hemopoietic reserve in the older cancer patient: clinical and economic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Update of the economic analyses of the use of the colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

A predictive model for neutropenia associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

Filgrastim in patients with neutropenia: potential effects on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000607

10.1177/107327480301000607

21 January 2018

Identifiers

DOI

0 references

1 reference